HRCM
PTCT icon

Hood River Capital Management’s PTC Therapeutics PTCT Stock Holding History

Hood River Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113M Buy
1,664,559
+661,484
+66% +$46.8M 1.14% 21
2025
Q4 		$76.2M Buy
1,003,075
+7,293
+0.7% +$530K 0.84% 42
2025
Q3 		$61.1M Buy
995,782
+359,280
+56% +$18.7M 0.72% 53
2025
Q2 		$31.1M Buy
636,502
+552,130
+654% +$26.2M 0.43% 84
2025
Q1 		$4.3M Buy
+84,372
New +$4.21M 0.07% 129

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Hood River Capital Management's PTCT Position: Q1 2026 in Review

Hood River Capital Management increased its PTC Therapeutics (PTCT) stake by 66% in Q1 2026, buying an estimated $46.8M and bringing the position to 1,664,559 shares worth $113M. The position accounts for 1.14% of the portfolio, ranked #21.

Hood River Capital Management first reported a position in PTCT in Q1 2025 and has held it in 5 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Hood River Capital Management held 1,664,559 shares of PTC Therapeutics worth $113M as of Q1 2026.
  • Hood River Capital Management bought 661,484 PTC Therapeutics shares in Q1 2026, an estimated $46.8M.
  • PTC Therapeutics made up 1.14% of Hood River Capital Management's portfolio in Q1 2026, its #21 holding.
  • Hood River Capital Management first reported a position in PTC Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.